Company Overview and News

 
Brian Gaynor: Cannabis stocks don't take long to get high

2017-05-12 nzherald.co.nz
Global sharemarkets are going to pot as a large number of marijuana companies have listed in recent years, including on the Australian sharemarket.
Upvote Downvote

 
Zelda Therapeutics Ltd starts countdown to ASX listing

2016-10-26 proactiveinvestors.com.au
Zelda Therapeutics Ltd's (ASX:ZLD) transition to being a publically listed medical cannabis focused company is almost complete.
Upvote Downvote

 
Zelda Therapeutics receives $4M worth of interest

2016-10-12 proactiveinvestors.com.au
Zelda Therapeutics Ltd (ASX:ZLD) has been formed through the reverse-takeover of the previously ASX-listed Gleneagle Gold Ltd.
Upvote Downvote

 
Gleneagle Gold Ltd raises $4M ahead of name change to Zelda Therapeutics Ltd

2016-09-20 proactiveinvestors.com.au
Gleneagle Gold (ASX:GLN) has positioned itself to transition into the medical cannabis sector after entering into an agreement to acquire Zelda Therapeutics Pty Ltd.
Upvote Downvote

 
Gleneagle / Zelda Therapeutics Ltd outlines medical cannabis strategy with investors

2016-08-05 proactiveinvestors.com.au
Gleneagle Gold (ASX:GLN) has positioned itself to transition into the medical cannabis sector after entering into an agreement to acquire Zelda Therapeutics Pty Ltd.
Upvote Downvote

 
Proactive Spotlight CEO Sessions: Gain Access to August Presentations

2016-08-04 proactiveinvestors.com.au
The Proactive's Spotlight CEO Sessions exclusively featured Medical Cannabis, Agriculture, Biotech and Industrial in Sydney this week.
Upvote Downvote

 
Proactive Spotlight CEO Investor Sessions: Cellmid, Anatara, Hazer, Zelda Therapeutics, Real Estate Investar

2016-07-25 proactiveinvestors.com.au
Proactive Investors is delighted to invite you to attend Proactive's Spotlight CEO Investor Session in Sydney on Wednesday 3rd August 2016. It promises to be another fascinating Investor Session. Registrations are already filling up, so you better be quick. REGISTER HERE: Wednesday, 3rd August
Upvote Downvote

 
Proactive Spotlight CEO Investor Sessions: Cellmid, Anatara, Hazer, Zelda Therapeutics

2016-07-21 proactiveinvestors.com.au
Proactive Investors is delighted to invite you to attend Proactive's Spotlight CEO Investor Session in Sydney on Wednesday 3rd August 2016. It promises to be another fascinating Investor Session. Registrations are already filling up, so you better be quick. REGISTER HERE: Wednesday, 3rd August
Upvote Downvote

 
Gleneagle Gold Ltd brings medical cannabis to Proactive's CEO Spotlight Sessions

2016-07-19 proactiveinvestors.com.au
Gleneagle Gold (ASX:GLN) has positioned itself to transition into the medical cannabis sector after entering into an agreement to acquire Zelda Therapeutics Pty Ltd.
Upvote Downvote

 
Gleneagle Gold Ltd receives notice of initial substantial holder

2016-07-10 proactiveinvestors.com.au
Gleneagle Gold (ASX:GLN) has positioned itself to transition into the medical cannabis sector after entering into an agreement to acquire Zelda Therapeutics Pty Ltd.
Upvote Downvote

 
Gleneagle Gold Ltd to consolidate shares ahead of medical cannabis transition

2016-06-29 proactiveinvestors.com.au
Gleneagle Gold (ASX:GLN) has positioned itself to transition into the medical cannabis sector after entering into an agreement to acquire Zelda Therapeutics Pty Ltd.
Upvote Downvote

 
Gleneagle Gold Ltd outlines final timeline to medicinal cannabis transition

2016-06-21 proactiveinvestors.com.au
Gleneagle Gold (ASX:GLN) has positioned itself to transition into the medical cannabis sector after entering into an agreement to acquire Zelda Therapeutics Pty Ltd.
Upvote Downvote

 
 
Gleneagle Gold Ltd is well-advanced in transition to medical cannabis

2016-05-05 proactiveinvestors.com.au
Gleneagle Gold (ASX:GLN) has positioned itself to transition into the medical cannabis sector after entering into an agreement to acquire Zelda Therapeutics Pty Ltd.
Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

2018-04-25 - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

2018-04-25 - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...